- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Katie Goodman Discusses Clinical Trial Participation Criteria's Impact on Trial Participation
Clinical trial criteria is really about patient safety and making sure participating patients don't experience undue risks, explained Katie Goodman, RN, BSN, CCRP, director of clinical research, Florida Cancer Specialists & Research Institute.
Clinical trial criteria is really about patient safety and making sure participating patients don't experience undue risks, explained Katie Goodman, RN, BSN, CCRP, director of clinical research, Florida Cancer Specialists & Research Institute.
Transcript
How does current clinical trial criteria limit participation in clinical trials among patients with cancer?
Cancer is a complicated disease and it is a disease of the elderly, so often times, there are other disease states that are happening. They might have cardiovascular disease or high blood pressure, for example. Or have had maybe a prior cancer and this is not their first cancer. So, clinical trials define who can participate and can be very detailed, down to do they have controlled hypertension, for example. If perhaps it’s not controlled, then sometimes a clinical trial will tend to not want that patient to participate.
It’s really about patient safety, and I think that that’s what is in mind when they are writing these protocols, to really make sure that the patients that are participating in investigational therapy are not going to unintentionally have undue risks that we don’t want to happen with the average patient. So yes, we do have to think about that, and we do have to consider the total patient and not just the cancer when we’re deciding whether or not a patient is able to participate in a clinical trial. Those things are typically defined up front, and conversations can happen with the patient along the way before they ever even start to participate.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More
